Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Apr 11;11(1):234-238.
doi: 10.1159/000488447. eCollection 2018 Jan-Apr.

Bexarotene-Induced Hypertriglyceridemia: A Case Report

Chris Maminakis  1 , Arin C Whitman  2 , Nahida Islam  2
Affiliations
Case Reports

Bexarotene-Induced Hypertriglyceridemia: A Case Report

Chris Maminakis et al. Case Rep Oncol. .

Abstract

We present a case of a patient with cutaneous T-cell lymphoma started on bexarotene 300 mg/m2 due to progressing disease. The patient experienced good clinical response, but unfortunately, she developed rapid and profound hypertriglyceridemia. Although hypertriglyceridemia occurs in high incidence with bexarotene therapy, management recommendations are scarce. Due to the rise in triglycerides, atorvastatin 10 mg daily was initiated in combination with fenofibrate 120 mg daily. Triglycerides continued to increase, so the patient was instructed to take atorvastatin 40 mg, fenofibrate 120 mg, and to hold bexarotene for 2 weeks. After the 2-week break, bexarotene was restarted at 150 mg/m2.

Keywords: Bexarotene; Cutaneous T-cell lymphoma; Hypertriglyceridemia.

PubMed Disclaimer

References

    1. Targretin [package insert]. Bridgewater (NJ): Valeant Pharmaceuticals North America LLC; 2015. [cited 2018 Feb 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021055s010lbl.pdf.
    1. Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013 Jan;168((1)):192–200. - PubMed
    1. Quéreux G, Saint-Jean M, Peuvrel L, Brocard A, Knol AC, Dréno B. Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature. Expert Opin Pharmacother. 2013 Sep;14((13)):1711–1721. - PubMed
    1. Willemze R, Hodak E, Zinzani PL, et al. Primary Cutaneous Lymphoma: ESMO Clinical Practice Guidelines. Ann Oncol. 2013;24(Suppl 6):vi149–vi154. - PubMed
    1. Lalloyer F, Pedersen TA, Gross B, Lestavel S, Yous S, Vallez E, et al. Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver. Arterioscler Thromb Vasc Biol. 2009 Oct;29((10)):1488–1495. - PMC - PubMed

Publication types

LinkOut - more resources